Patents by Inventor Peter Madsen

Peter Madsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Pegylated Single-Chain Insulin

Publication number: 20100216690

Abstract: The present invention is related to a single-chain insulin comprising the B- and the A-chain of human insulin or analogues thereof connected by a connecting peptide having from 3-35 amino acid residues, wherein the single-chain insulin comprises at least one PEG group attached to at least one lysine residue in the single-chain insulin molecule and/or to the B1 N terminal amino acid residue. The PEGylated single-chain insulins may comprise up to 4 PEG groups which may be the same or different.

Type: Application

Filed: March 17, 2006

Publication date: August 26, 2010

Applicant: Novo Nordisk A/S

Inventors: Peter Madsen, Thomas Borglum Kjeldsen
Novel Insulin Derivatives

Publication number: 20100009899

Abstract: The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: —W—X—Y—Z wherein W, X, Y and Z are as defined in the disclosure.

Type: Application

Filed: September 16, 2009

Publication date: January 14, 2010

Applicant: Novo Nordisk A/S

Inventors: Ib Jonassen, Thomas Hoeg-Jensen, Svend Havelund, Ulla Ribel-Madsen, Tina Møller Tagmose, Peter Madsen
Pegylated, Extended Insulins

Publication number: 20090306337

Abstract: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regulär insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.

Type: Application

Filed: July 16, 2007

Publication date: December 10, 2009

Applicant: Novo Nordisk A/S

Inventors: Peter Madsen, Thomas Børglum Kjeldsen, Tina Møller Tagmose, Palle Jakobsen
Insulin derivatives

Patent number: 7615532

Abstract: The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: -W-X—Y-Z wherein W, X, Y and Z are as defined in the disclosure.

Type: Grant

Filed: January 30, 2006

Date of Patent: November 10, 2009

Assignee: Novo Nordisk A/S

Inventors: Ib Jonassen, Thomas Hoeg-Jensen, Svend Havelund, Ulla Ribel-Madsen, Tina Møller Tagmose, Peter Madsen
Single-Chain Insulin

Publication number: 20090170750

Abstract: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.

Type: Application

Filed: October 15, 2008

Publication date: July 2, 2009

Applicant: Novo Nordisk A/S

Inventors: Thomas Borglum Kjeldsen, Asser Sloth Andersen, Morten Schlein, Anders Robert Sorensen, Peter Madsen
Glucagon Antagonists/Inverse Agonists

Publication number: 20090143592

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

Type: Application

Filed: December 3, 2007

Publication date: June 4, 2009

Applicant: Novo Nordisk A/S

Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi
Insulin Derivatives

Publication number: 20090137454

Abstract: The present invention is related to insulin derivatives having a side chain attached to an ?-amino group of a Lys residue present in the A-chain or to an ?-amino group of a Lys residue in the B-chain.

Type: Application

Filed: February 27, 2007

Publication date: May 28, 2009

Applicant: NOVO NORDISK A/S

Inventors: Charlotte Harkjaer Fynbo, Ib Jonassen, Thomas Borglum Kjeldsen, Peter Madsen, Patrick William Garibay, Janos Tibor Kodra, Thomas Hoeg-Jensen, Tina Moller Tagmose
Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand

Publication number: 20090123563

Abstract: Novel preparations comprising branched ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The preparations have a prolonged action designed for flexible injection regimes.

Type: Application

Filed: February 6, 2006

Publication date: May 14, 2009

Applicant: NOVO NORDISK A/S

Inventors: Niels Christian Kaarsholm, Helle Birk Olsen, Peter Madsen, Soeren Ostegaard, Palle Jakobsen, Tina Moeller Tagmose
Acylated Single Chain Insulin

Publication number: 20090099065

Abstract: The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in one of the positions A12-A23 in the human insulin A-chain has been chemically modified by acylation.

Type: Application

Filed: March 12, 2007

Publication date: April 16, 2009

Applicant: Novo Nordisk A/S

Inventors: Peter Madsen, Thomas Borglum Kjeldsen, Tina Moller Tagmose
Acylated Single Chain Insulin

Publication number: 20090069215

Abstract: The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in at least one of the positions B20, B21 or B22 in the human insulin B-chain is chemically modified by acylation.

Type: Application

Filed: March 12, 2007

Publication date: March 12, 2009

Applicant: Novo Nordisk A/S

Inventors: Peter Madsen, Thomas Borglum Kjeldsen, Tina Moller Tagmose
Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers

Publication number: 20090036353

Abstract: Insulin conjugated with structurally well defined, bifurcated and trifurcated polymers can be use by pulmonary delivery for systemic absorption through the lungs to reduce or eliminate the need for administering other insulins by injection.

Type: Application

Filed: January 26, 2006

Publication date: February 5, 2009

Applicant: Novo Nordisk A/S

Inventors: Carsten Behrens, Jesper Lau, Janos Tibor Kodra, Mikael Kofod-Hansen, Thomas Hoeg-Jensen, Peter Madsen, Svend Havelund
Insulin Derivatives

Publication number: 20080171695

Abstract: The present invention is related to insulin derivatives having a side chain attached either to the ?-amino group of the N-terminal amino acid residue of B chain or to an ?-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond which side chain comprises one or more residues of ethyleneglycol, propyleneglycol and/or butyleneglycol containing independently at each termini a group selected from —NH2 and —COOH; a fatty diacid moiety with 4 to 22 carbon atoms, at least one free carboxylic acid group or a group which is negatively charged at neutral pH; and possible linkers which link the individual components in the side chain together via amide or ether bonds, said linkers optionally comprising a free carboxylic acid group.

Type: Application

Filed: February 1, 2006

Publication date: July 17, 2008

Applicant: Novo Nordisk A/S

Inventors: Patrick William Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Svend Havelund, Peter Madsen, Palle Jakobsen
Insulin Derivatives

Publication number: 20080076705

Abstract: The present invention relates to insulin derivatives having a side chain attached either to the -amino group of the N-terminal amino acid residue of the B chain or to the amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.

Type: Application

Filed: February 1, 2006

Publication date: March 27, 2008

Inventors: Janos Kodra, Patrick Garibay, Thomas Hoeg-Jensen, Ib Jonassen, Peter Madsen, Tina Tagmose
Single-chain insulin

Publication number: 20070129284

Abstract: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.

Type: Application

Filed: May 24, 2006

Publication date: June 7, 2007

Applicant: Novo Nordisk A/S

Inventors: Thomas Kjeldsen, Asser Andersen, Morten Schlein, Anders Sorensen, Peter Madsen
Novel Glucagon Antagonists/Inverse Agonists

Publication number: 20070015757

Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.

Type: Application

Filed: June 18, 2006

Publication date: January 18, 2007

Applicant: Novo Nordisk A/S

Inventors: Peter Madsen, Jesper Lau, Janos Kodra, Inge Christensen
Novel NPH insulin preparations

Publication number: 20060258561

Abstract: This invention relates to NPH-insulin (crystalline preparations) that are prepared in the presence of certain high-affinity ligands for the HisB10 Zn2+-sites of the R-state insulin hexamer. Preparation of NPH-insulin in the presence of high-affinity ligand results in crystalline NPH-insulin suspensions that are absorbed more slowly from subcutis than regular NPH-insulin.

Type: Application

Filed: September 9, 2005

Publication date: November 16, 2006

Applicant: Novo Nordisk A/S

Inventors: Per Balschmidt, Helle Olsen, Niels Kaarsholm, Peter Madsen, Palle Jakobsen, Svend Ludvigsen, Gerd Schluckebier, Dorte Steensgaard, Anders Petersen
Novel insulin derivatives

Publication number: 20060183668

Abstract: The present invention relates to insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the ?-amino group of the N-terminal amino acid residue of the B chain or to the ?-amino group of a Lys residue present in the B chain of the parent insulin, the side chain being of the general formula: -W-X-Y-Z wherein W, X, Y and Z are as defined in the disclosure.

Type: Application

Filed: January 30, 2006

Publication date: August 17, 2006

Applicant: Novo Nordisk A/S

Inventors: Ib Jonassen, Thomas Hoeg-Jensen, Svend Havelund, Ulla Ribel-Madsen, Tina Tagmose, Peter Madsen
Pharmaceutical preparations comprising acid-stabilised insulin

Publication number: 20060069013

Abstract: Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

Type: Application

Filed: September 12, 2005

Publication date: March 30, 2006

Applicant: Novo Nordisk A/S

Inventors: Soren Ostergaard, Helle Olsen, Niels Kaarsholm, Peter Madsen, Palle Jakobsen, Svend Ludvigsen, Gerd Schluckebier, Dorte Steensgaard, Anders Petersen
Novel glucagon antagonists/inverse agonists

Publication number: 20050256175

Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.

Type: Application

Filed: February 22, 2005

Publication date: November 17, 2005

Inventors: Jesper Lau, Inger Christensen, Peter Madsen, Paw Bloch, Carsten Behrens, Janos Kodra, Poul Nielsen
Glucagon antagonists/inverse agonists

Patent number: 6953812

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

Type: Grant

Filed: February 24, 2003

Date of Patent: October 11, 2005

Assignee: Novo Nordisk, Inc.

Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau

prev 1 2 3 4 5 6 7 8 9 next